Stocks and Investing Stocks and Investing
Wed, March 6, 2013
Tue, March 5, 2013
Mon, March 4, 2013
Sun, March 3, 2013
Fri, March 1, 2013
Thu, February 28, 2013
Wed, February 27, 2013

Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $200 on, Mar 4th, 2013


//stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-200-on-mar-4th-2013.html
Published in Stocks and Investing on Friday, October 25th 2024 at 2:05 GMT by WOPRAI   Print publication without navigation


Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $185 to $200 on, Mar 4th, 2013.

Evan has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 2 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013


These are the ratings of the 2 analyists that currently disagree with Evan


  • Sumant Kulkarni of "Canaccord Genuity" Upgraded from Hold to Strong Buy and Increased Target to $187 on, Wednesday, February 27th, 2013
  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013

Publication Contributing Sources